Palo Alto, CA, United States of America

Stephen Kelsey

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2016-2025

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Stephen Kelsey

Introduction

Stephen Kelsey is a notable inventor based in Palo Alto, California. He has made significant contributions to the field of medical research, particularly in the treatment of myeloproliferative disorders. With a total of 2 patents to his name, Kelsey is recognized for his innovative approaches to healthcare.

Latest Patents

Kelsey's latest patents focus on the use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms. These patents provide methods for reducing neoplastic progenitor cell proliferation and alleviating symptoms associated with individuals diagnosed with or suspected of having Essential Thrombocythemia (ET). Additionally, the patents outline methods for using telomerase inhibitors to maintain blood platelet counts within relatively normal ranges for those affected by ET.

Career Highlights

Stephen Kelsey is currently associated with Geron Corporation, where he continues to advance his research and innovations. His work has been instrumental in developing new therapeutic strategies for patients suffering from blood disorders.

Collaborations

Kelsey collaborates with various professionals in his field, including Monic J Stuart, to enhance the impact of his research and innovations.

Conclusion

Stephen Kelsey is a prominent inventor whose work in the medical field has the potential to improve the lives of many individuals affected by myeloproliferative disorders. His innovative patents and ongoing research at Geron Corporation highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…